Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions

By sjmartinez • October 24, 2023

Zhou C, Tang KJ, Cho BC, Liu B, Paz-Ares L, Cheng S, Kitazono S, Thiagarajan M, Goldman JW, Sabari JK, Sanborn RE, Mansfield AS, Hung JY, Boyer M, Popat S, Mourão Dias J, Felip E, Majem M, Gumus M, Kim SW, Ono A, Xie J, Bhattacharya A, Agrawal T, Shreeve SM, Knoblauch RE, Park K, Girard N; PAPILLON Investigators. Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions. N Engl J Med. 2023 Oct 21. doi: 10.1056/NEJMoa2306441. Epub ahead of print. PMID: 37870976.

Tags: Hematology/Oncology, Publications

Characteristics of clinical trials associated with appeal and return on investment to participants, A Review and Framework

Fernandez Turizo MJ, Velez MA, Glenn B, Cummings AL, Segarra-Vazquez B, Gorbatov S, Park SJ, Shen C, Lind-Lebuffe JP, Unger JM, Garon EB. Characteristics of[...]

IGF2BP3 redirects glycolytic flux to promote one-carbon metabolism and RNA methylation

Sharma G, Gutierrez M, Jones AE, Kapoor S, Jaiswal AK, Neeb ZT, Rios A, Dorairaj P, Thaxton ML, Lin TL, Tran TM, Kabbani LES, Ritter[...]

Ribociclib Plus Endocrine Therapy in Hormone Receptor-Positive/ERBB2-Negative Early Breast Cancer: 4-Year Outcomes From the NATALEE Randomized Clinical Trial

Fasching PA, Stroyakovskiy D, Yardley DA, Huang CS, Crown J, Bardia A, Chia S, Im SA, Martin M, Xu B, Loi S, Barrios C, Untch[...]